⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18205537 | 0.97 | OPRM1 (0.57) | — | |
| SCHEMBL2927490 | 0.90 | — | — | |
| SCHEMBL2470486 | 0.83 | — | — | |
| SCHEMBL901170 | 0.79 | — | — | |
| SCHEMBL27976138 | 0.78 | OPRM1 (0.63) | — | |
| Hexane SCHEMBL16244743 | 0.78 | OPRM1 (0.63) | — | |
| SCHEMBL5505561 | 0.78 | — | — | |
| SCHEMBL672857 | 0.78 | OPRM1 (0.63) | — | |
| SCHEMBL29533 | 0.78 | — | — | |
| SCHEMBL615266 | 0.78 | OPRM1 (0.63) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107820496-B | Tetracyclic 4-oxo-pyridine-3-carboxylic acid derivatives for the treatment and prevention of hepatitis B virus infections | 豪夫迈·罗氏有限公司 | 2020-11-03 | — | — | CN | claimed |
| CN-107624113-B | Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of HBsAg (HBV surface antigen) and HBV DNA production for the treatment of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2020-10-23 | — | — | CN | claimed |
| CN-107849037-B | Tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prevention of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2020-04-17 | — | — | CN | claimed |
| US-10336751-B2 | Tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2019-07-02 | — | — | US | claimed |
| EP-3292120-B1 | TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES AS INHIBITORS OF HBSAG (HBV SURFACE ANTIGEN) AND HBV DNA PRODUCTION FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTIONS | HOFFMANN LA ROCHE (CH) | 2019-06-19 | — | — | EP | claimed |
| EP-3328855-B1 | NOVEL TETRACYCLIC 4-OXO-PYRIDINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2019-05-15 | — | — | EP | claimed |
| EP-3325477-B1 | NOVEL TRICYCLIC 4-PYRIDONE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2019-05-01 | — | — | EP | claimed |
| US-10053461-B2 | Tetracyclic 4-oxo-pyridine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2018-08-21 | — | — | US | claimed |
| EP-3328855-A1 | NOVEL TETRACYCLIC 4-OXO-PYRIDINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | H. Hoffnabb-La Roche Ag (CH) | 2018-06-06 | — | — | EP | claimed |
| US-20180134705-A1 | NOVEL TRICYCLIC 4-PYRIDONE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2018-05-17 | — | — | US | claimed |
| US-20180127416-A1 | NOVEL TETRACYCLIC 4-OXO-PYRIDINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2018-05-10 | — | — | US | claimed |
| EP-3292120-A1 | TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES AS INHIBITORS OF HBSAG (HBV SURFACE ANTIGEN) AND HBV DNA PRODUCTION FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTIONS | H. Hoffnabb-La Roche Ag (CH) | 2018-03-14 | — | — | EP | claimed |
| US-9845322-B2 | Tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2017-12-19 | — | — | US | claimed |
| WO-2017017042-A1 | NOVEL TETRACYCLIC 4-OXO-PYRIDINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2017-02-02 | — | — | WO | claimed |
| WO-2016177655-A1 | TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES AS INHIBITORS OF HBSAG (HBV SURFACE ANTIGEN) AND HBV DNA PRODUCTION FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-11-10 | — | — | WO | claimed |
| US-20160326167-A1 | Novel Tetrahydropyridopyrimidines and Tetrahydropyridopyridines for the Treatment and Prophylaxis of Hepatitis B Virus Infection | HOFFMANN-LA ROCHE INC. (US) | 2016-11-10 | — | — | US | claimed |
| US-6762169-B1 | IMPROVED TRANSMEMBRANE DELIVERY OF NUCLEOSIDES CONJUGATED TO AN ARYLPROPIONIC ACID LIGAND (IBUPROFEN) WHICH HAS AFFINITY FOR PLASMA PROTEIN ALBUMIN; ANTISENSE THERAPY | ISIS PHARMACEUTICALS, INC. | 2004-07-13 | — | — | US | claimed |
| US-11891558-B2 | Solid foam comprising mesogenic ligand-functionalized nanoparticles and methods of making and using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-02-06 | — | — | US | disclosed |
| WO-2016177655-A1 | TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES AS INHIBITORS OF HBSAG (HBV SURFACE ANTIGEN) AND HBV DNA PRODUCTION FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-11-10 | — | — | WO | disclosed |
| WO-2016106377-A1 | THREE-DIMENSIONAL STRUCTURES OF MESOGENIC LIGAND-FUNCTIONALIZED NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-06-30 | — | — | WO | disclosed |